

(d) Since neither of the two SEZs proposals were implemented, no exports were effected from the SEZs and no employment provided.

Impact of regulatory action by USFDA on exports

1138. SHRI SANJAY RAUT: Will the Minister of COMMERCE AND INDUSTRY be pleased to state:

(a) whether it is a fact that the regulatory action by the US Food and Drug Administration (USFDA) are hurting and impacted exports from the country and drug industry has urged Government for the early intervention and dialogue with US health regulator;

(b) if so, Government's response and reaction thereto; and

(c) the details of steps taken or proposed to be taken by Government to grow our domestic drug industry to their potential in international market?

THE MINISTER OF STATE OF THE MINISTRY OF COMMERCE AND INDUSTRY (SHRIMATI NIRMALA SITHARAMAN): (a) and (b) Despite the regulatory action by the US Food and Drug Administration (USFDA), Indian pharmaceutical exports to United States have increased from \$ 3.4 billion in 2013-14 to \$ 3.8 billion in 2014-15 (Source: Export Import Data Bank of Ministry of Commerce and Industry). There is no representation from the industry to Government for early intervention and dialogue with US Health regulator.

(c) India and US are collaborating in information sharing about Good Manufacturing Practices, inspections, capacity building of inspectors and industry.

Continuous fall in exports

1139. SHRI NEERAJ SHEKHAR: Will the Minister of COMMERCE AND INDUSTRY be pleased to state:

(a) whether exports have fallen for 15th and 16th consecutive months in February and March, 2016;

(b) if so, the details thereof; and

(c) the reasons for continuous fall in exports for the past 16 months?

THE MINISTER OF STATE OF THE MINISTRY OF COMMERCE AND INDUSTRY (SHRIMATI NIRMALA SITHARAMAN): (a) and (b) The month-wise details of India's exports for the last 16 months from December, 2014 to March, 2016 are as under: